Skip to main content
. Author manuscript; available in PMC: 2013 Oct 8.
Published in final edited form as: Vaccine. 2010 May 14;28(30):4837–4841. doi: 10.1016/j.vaccine.2010.04.057

Fig. 2.

Fig. 2

Lymphoproliferative response of PBMC 2 months after the initial injection (timepoint I at month 2), 4 months after the second injection (timepoint II at month 6) and 2 months after the third and final immunization (timepoint III at month 8). Vaccinated and non-vaccinated controls were grouped and results are shown as the mean cpm +/−SD. Vaccinated immuno-competents (white) showed significantly lymphoproliferative responses already 2 months after the first injection at timepoint I, whereas PBMC of non-vaccinated immuno-competent controls (black) did not proliferate in response to addition of the HPV vaccine. In the WHIM patient (grey) proliferation was detectable at timepoints II and III.